Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)
First gene therapy for a rare genetic brain disorder showed potential to slow cognitive decline, though patients need careful monitoring for liver complications.
This regulatory evidence review of an open-label study with external natural-history controls examined Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA). The first approved disease-modifying therapy for MPS IIIA improved modeled cognitive outcomes and lowered cerebrospinal-fluid heparan sulfate, with substantial liver-enzyme elevations and serious adverse events requiring follow-up.
What the study was
- Study design
- Regulatory evidence review of an open-label study with external natural-history controls
- Population
- Young children with mucopolysaccharidosis type IIIA and preserved neurodevelopmental function
- Sample size
- 17 early-treated patients and 27 external controls
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Drug discoveries & therapeutics
Why it surfaced
Regulatory evidence review of an open-label study with external natural-history controls; The first approved disease-modifying therapy for MPS IIIA improved modeled cognitive outcomes and lowered cerebrospinal-fluid heparan sulfate, with substantial liver-enzyme elevations and serious adverse events requiring follow-up. Score kept conservative because only the PubMed abstract and metadata were reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.